- Home
- BEATW vs XYL Comparison
BEATW vs XYL Comparison
Compare BEATW & XYL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BEATW
- XYL
- Stock Information
- Founded
- BEATW 2015
- XYL 2011
- Country
- BEATW United States
- XYL United States
- Employees
- BEATW 21
- XYL N/A
- Industry
- BEATW Retail: Computer Software & Peripheral Equipment
- XYL Fluid Controls
- Sector
- BEATW Technology
- XYL Industrials
- Exchange
- BEATW Nasdaq
- XYL Nasdaq
- Market Cap
- BEATW N/A
- XYL N/A
- IPO Year
- BEATW N/A
- XYL N/A
- Fundamental
- Price
- BEATW $0.60
- XYL $116.10
- Analyst Decision
- BEATW
- XYL Buy
- Analyst Count
- BEATW 0
- XYL 10
- Target Price
- BEATW N/A
- XYL $147.33
- AVG Volume (30 Days)
- BEATW 4.7K
- XYL 2.2M
- Earning Date
- BEATW 03-14-2025
- XYL 04-29-2025
- Dividend Yield
- BEATW N/A
- XYL 1.38%
- EPS Growth
- BEATW N/A
- XYL 30.82
- EPS
- BEATW N/A
- XYL 3.65
- Revenue
- BEATW N/A
- XYL $8,562,000,000.00
- Revenue This Year
- BEATW N/A
- XYL $3.17
- Revenue Next Year
- BEATW N/A
- XYL $5.25
- P/E Ratio
- BEATW N/A
- XYL $31.76
- Revenue Growth
- BEATW N/A
- XYL 16.27
- 52 Week Low
- BEATW $0.50
- XYL $100.47
- 52 Week High
- BEATW $0.62
- XYL $146.08
- Technical
- Relative Strength Index (RSI)
- BEATW N/A
- XYL 53.69
- Support Level
- BEATW N/A
- XYL $107.04
- Resistance Level
- BEATW N/A
- XYL $116.32
- Average True Range (ATR)
- BEATW 0.00
- XYL 4.06
- MACD
- BEATW 0.00
- XYL 1.29
- Stochastic Oscillator
- BEATW 0.00
- XYL 98.36
About BEATW Heartbeam Inc.
HeartBeam Inc is a medical technology company primarily focusing on developing and commercializing higher resolution ambulatory Electrocardiogram ("ECG") solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company's ability to develop higher-resolution ECG solutions is achieved through the development of the Company's proprietary and patented Vector Electrocardiography ("VECG") technology platform. The Company has validated this technology and is seeking U.S. Food and Drug Administration ("FDA") clearance for its initial telehealth products.